Confidence Interval Estimation for Sensitivity to the Early Diseased Stage Based on Empirical Likelihood

The generalized order statistics arising from three populations with the lower truncated proportional hazard rate models and its application to the sensitivity to the early disease stage

In this paper, we present some results to make inference about the parameters of lower truncated proportional hazard rate models with the same baseline distributions based on three independent generalized order statistics samples. Then, especially by considering the results of the diagnostic tests for the non-diseased, early-diseased stage and fully diseased populations, we make inference about sensitivity to the early disease stage parameter. The maximum likelihood estimator, a generalized pivotal estimator and some Bayes estimators are obtained for different structures of prior distributions. The percentile bootstrap confidence interval, a generalized pivotal confidence interval and some Bayesian credible intervals are also presented. A Monte Carlo simulation study is used to evaluate the performances of the obtained point estimators and confidence/credible intervals and two competitors. We use two real datasets to illustrate the proposed methods.

Interval estimation in three-class receiver operating characteristic analysis: A fairly general approach based on the empirical likelihood

The empirical likelihood is a powerful nonparametric tool, that emulates its parametric counterpart-the parametric likelihood-preserving many of its large-sample properties. This article tackles the problem of assessing the discriminatory power of three-class diagnostic tests from an empirical likelihood perspective. In particular, we concentrate on interval estimation in a three-class receiver operating characteristic analysis, where a variety of inferential tasks could be of interest. We present novel theoretical results and tailored techniques studied to efficiently solve some of such tasks. Extensive simulation experiments are provided in a supporting role, with our novel proposals compared to existing competitors, when possible. It emerges that our new proposals are extremely flexible, being able to compete with contestants and appearing suited to accommodating several distributions, such, for example, mixtures, for target populations. We illustrate the application of the novel proposals with a real data example. The article ends with a discussion and a presentation of some directions for future research.

Bayesian and influence function-based empirical likelihoods for inference of sensitivity to the early diseased stage in diagnostic tests

In practice, a disease process might involve three ordinal diagnostic stages: the normal healthy stage, the early stage of the disease, and the stage of full development of the disease. Early detection is critical for some diseases since it often means an optimal time window for therapeutic treatments of the diseases. In this study, we propose a new influence function-based empirical likelihood method and Bayesian empirical likelihood methods to construct confidence/credible intervals for the sensitivity of a test to patients in the early diseased stage given a specificity and a sensitivity of the test to patients in the fully diseased stage. Numerical studies are performed to compare the finite sample performances of the proposed approaches with existing methods. The proposed methods are shown to outperform existing methods in terms of coverage probability. A real dataset from the Alzheimer's Disease Neuroimaging Initiative (ANDI) is used to illustrate the proposed methods.

Empirical likelihood confidence interval for sensitivity to the early disease stage

Disease status can naturally be classified into three or more ordinal stages rather than just being binary stages. Many works have been done for the estimation and inference procedure regarding three ordinal disease stages, which are non-disease, early disease, and full disease stages. The early disease stage can be very important for therapeutic intervention and prevention potentiality. As a diagnostic measure, sensitivity to the early disease stage is often used. In this article, we propose confidence intervals for the sensitivity to early disease stage based on given target specificity for non-disease stage and target sensitivity to full disease stage using both empirical likelihood (EL) and adjusted EL procedures. We compare the performance of the proposed EL confidence intervals with other procedures in our simulation study. The proposed procedures are further applied to Alzheimer's Disease Neuroimaging Initiative data set.

Bayesian and influence function-based empirical likelihoods for inference of sensitivity in diagnostic tests

In medical diagnostic studies, a diagnostic test can be evaluated based on its sensitivity under a desired specificity. Existing methods for inference on sensitivity include normal approximation-based approaches and empirical likelihood (EL)-based approaches. These methods generally have poor performance when the specificity is high, and some require choosing smoothing parameters. We propose a new influence function-based empirical likelihood method and Bayesian empirical likelihood methods to overcome such problems. Numerical studies are performed to compare the finite sample performance of the proposed approaches with existing methods. The proposed methods are shown to perform better in terms of both coverage probability and interval length. A real data set from Alzheimer's Disease Neuroimaging Initiative (ANDI) is analyzed.

Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials

INTRODUCTION

The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued development and standardization of methodologies for biomarkers and has provided an increased depth and breadth of data available to qualified researchers. This review summarizes the over 400 publications using ADNI data during 2014 and 2015.

METHODS

We used standard searches to find publications using ADNI data.

RESULTS

(1) Structural and functional changes, including subtle changes to hippocampal shape and texture, atrophy in areas outside of hippocampus, and disruption to functional networks, are detectable in presymptomatic subjects before hippocampal atrophy; (2) In subjects with abnormal β-amyloid deposition (Aβ+), biomarkers become abnormal in the order predicted by the amyloid cascade hypothesis; (3) Cognitive decline is more closely linked to tau than Aβ deposition; (4) Cerebrovascular risk factors may interact with Aβ to increase white-matter (WM) abnormalities which may accelerate Alzheimer's disease (AD) progression in conjunction with tau abnormalities; (5) Different patterns of atrophy are associated with impairment of memory and executive function and may underlie psychiatric symptoms; (6) Structural, functional, and metabolic network connectivities are disrupted as AD progresses. Models of prion-like spreading of Aβ pathology along WM tracts predict known patterns of cortical Aβ deposition and declines in glucose metabolism; (7) New AD risk and protective gene loci have been identified using biologically informed approaches; (8) Cognitively normal and mild cognitive impairment (MCI) subjects are heterogeneous and include groups typified not only by "classic" AD pathology but also by normal biomarkers, accelerated decline, and suspected non-Alzheimer's pathology; (9) Selection of subjects at risk of imminent decline on the basis of one or more pathologies improves the power of clinical trials; (10) Sensitivity of cognitive outcome measures to early changes in cognition has been improved and surrogate outcome measures using longitudinal structural magnetic resonance imaging may further reduce clinical trial cost and duration; (11) Advances in machine learning techniques such as neural networks have improved diagnostic and prognostic accuracy especially in challenges involving MCI subjects; and (12) Network connectivity measures and genetic variants show promise in multimodal classification and some classifiers using single modalities are rivaling multimodal classifiers.

DISCUSSION

Taken together, these studies fundamentally deepen our understanding of AD progression and its underlying genetic basis, which in turn informs and improves clinical trial design.